Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer (STUNNIN): A Randomized Phase II Study

NCT05557604 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.

NCT NCT05557604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05557604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer (STUNNIN): A Randomized Phase II Study
Lead sponsor
Regina Elena Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2021
Completion date
February 2, 2027
Enrollment
146 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer